Martin Reck, MD, PhD, on Postsurgical MRD, Genomic Mutations, and Outcomes in Resectable NSCLC: AEGEAN Trial
2025 ASCO Annual Meeting
Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, discusses data from the phase III AEGEAN trial that studied perioperative durvalumab and neoadjuvant chemotherapy. Patients who were MRD-positive after surgery had significantly worse disease-free survival compared to MRD-negative patients. In addition, mutations in KEAP1 and KMT2C were associated with MRD positivity and reduced benefit from the regimen, identifying a small high-risk subgroup with poor prognosis (Abstract 8009).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
It's my pleasure to present here at the ASCO meeting the data of the MRD analysis from the AEGEAN trial in patients with resectable non-small cell lung cancer. While in the AEGEAN trial perioperative durvalumab with neoadjuvant chemotherapy improved event-free survival and pCR compared to chemotherapy alone, furthermore, we collected plasma samples during treatment, during the neoadjuvant therapy, before and after surgery, and at the adjuvant treatment. Here at ASCO, we reported data on patients who were MRD positive after surgery assessed by the ctDNA analysis. When we look at the biomarker-available population, 10% of the MRD-available patients were MRD positive, and when we look at patients' characteristics, these were mostly patients with locally advanced non-small cell lung cancer, patients with mediastinal lymph node metastasis. Compared to the MRD-negative patients, the MRD-positive patients had worse outcomes in terms of disease-free survival. We do see a trend favoring durvalumab versus placebo also in these patients. However, the trend was small. Furthermore, we looked at the genetic features of the patients who were diagnosed with MRD positivity in the ctDNA-available patients. We performed a whole exome analysis and in the 17 MRD-positive patients we found a number of mutations which do have an impact on IO response including KMT2C and the KEAP1 mutation. Therefore, in summary, what we have seen in this MRD analysis is that 10% are MRD positive. These patients do have a worse prognosis, and the whole exome analysis did show an association between certain mutations including KEAP1 and KMT2C and the MRD positivity. The numbers were small. However, this is a very important result which requires further investigation, because we have identified a poor prognostic group of patients with probably no benefit from the immunotherapy.
The ASCO Post Staff
David Allen Barbie, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews specific clinical and molecular features of early progressors and long-term progression-free survivors from the phase III ADRIATIC trial, which assessed consolidation durvalumab vs placebo after concurrent chemoradiotherapy for limited-stage small cell lung cancer (Abstract 8014).
The ASCO Post Staff
Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, reviews data from the global, randomized, phase III VERITAC-2 study, which compared vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor degrader, to fulvestrant among patients with ER-positive HER2-negative advanced breast cancer. Vepdegestrant is the first PROTAC to be evaluated in a phase III trial (Abstract LBA1000).
The ASCO Post Staff
Stephen K.L. Chia, MD, FRCPC, of BC Cancer Agency, reviews data from the phase III CCTG/BCT MA.40/FINER trial of fulvestrant and ipatasertib for advanced HER2-negative, ER-positive breast cancer following disease progression on first-line CDK 4/6 and aromatase inhibitors (LBA1005).
The ASCO Post Staff
South Florida has a unique demographic, characterized by a large Hispanic population with ancestries from the Caribbean and Central and South America. Arelis Esther Martir-Negron, MD, of Miami Cancer Institute, presents data from a retrospective analysis that sought to determine the frequency and spectrum of BRCA pathogenic/likely pathogenic variants in this population (Abstract 10579).
The ASCO Post Staff
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer (LBA4).